German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Outlook: targets by the end of 2023

Growth targets

  • to operate approx. 100 M1 Med Beauty outpatience clinics
  • to further increase inpatient clinic capacities
  • to be a leading lifestyle brand in aesthetic medicine
  • to be internationally known with our own brand for medical cosmetics

 

Latest news

| Corporate News

M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.

| Ad-hoc news

M1 Kliniken AG and HAEMATO AG today signed a contract for the acquisition of all shares in M1 Aesthetics GmbH by HAEMATO AG. M1 Kliniken AG will contribute M1 Aesthetics GmbH to HAEMATO AG within the scope of a capital increase through contribution in kind.

| Ad-hoc news

M1 Kliniken AG announces that as of today Mr. Patrick Brenske will join the Management Board of HAEMATO AG. At the same time, Mr. Brenske will resign from the Management
Board of M1 Kliniken AG, with Dr. Walter von Horstig from now on acting as sole member of the Management Board. Mr. Brenske will continue to advise M1.

| Corporate News

In contrast to the worsening pandemic situation, M1 Kliniken AG continues to record strong demand. The number of injection treatments and surgical treatments performed in the German market in the 3rd quarter of 2020 rose by almost 20% year-on-year to over 65,000.